IE
CCCC icon

Israel Englander’s C4 Therapeutics CCCC Stock Holding History

Israel Englander’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-25,000
Closed -$141K – 6215
2023
Q4 		$141K Buy
+25,000
New +$57K ﹤0.01% 5261
2022
Q2 		– Sell
-171,700
Closed -$4.17M – 7009
2022
Q1 		$4.17M Buy
+171,700
New +$4.17M ﹤0.01% 3129

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Israel Englander's CCCC Position: Q2 2026 in Review

Israel Englander reduced its C4 Therapeutics (CCCC) stake by 85% in Q2 2026, selling an estimated $4.03M and leaving 215,386 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #4309.

Israel Englander first reported a position in CCCC in Q4 2020 and has held it in 21 quarters since. The position peaked at $24.3M in Q4 2021. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Israel Englander held 215,386 shares of C4 Therapeutics worth $1.01M as of Q2 2026.
  • Israel Englander sold 1,177,956 C4 Therapeutics shares in Q2 2026, an estimated $4.03M.
  • C4 Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4309 holding.
  • Israel Englander first reported a position in C4 Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • Israel Englander's C4 Therapeutics position peaked at $24.3M in Q4 2021.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.